EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Blood N1-methyladenosine (m1A) RNA modification and outcome after cardiac arrest

Victoria Stopa, Miron Sopic, François Bernardin, Nathalie M Legrave, Lu Zhang, Pascal Stammet, Yvan Devaux

Critical Care · 2026

DOI: 10.1186/s13054-026-05906-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Critical Care, 2026. Verfasst von Victoria Stopa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Research Unit, Department of Precision Health, Institute of Health, 1A-B rue Edison, Strassen, L-1445, Luxembourg. Hauptthemen laut MEDLINE: Adenosine, Heart Arrest, RNA. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fondation Coeur Daniel Wagner, Ministère de l'Enseignement Supérieur et de la Recherche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Cardiac arrest (CA) is a leading cause of mortality and neurological disability. Prediction of post-CA outcomes is challenging. Epitranscriptomic (RNA) modifications are emerging as potential biomarkers due to their regulatory roles in RNA metabolism and disease progression. However, their relevance in CA remains unexplored. OBJECTIVE: This study aimed to investigate the association between N1-methyladenosine (m¹A) RNA modification and outcome after CA. METHODS: Total RNA was extracted from whole blood samples of 211 patients collected 48 h after return of spontaneous circulation (ROSC). M¹A and adenosine (A) blood levels were quantified using liquid chromatography coupled to mass spectrometry (LC-MS), and the ratio m¹A/A was calculated. Neurological outcome assessed using the cerebral performance category (CPC) score and survival at 6 months were used as end-points. RESULTS: Patients with moderate to severe neurological outcome or death within 6 months after CA (CPC 2–5) exhibited elevated m¹A/A ratio compared to survivors without neurological sequelae (CPC 1) (p = 0.03). In multivariable logistic regression, higher m1A/A levels were associated with an increased risk of moderate to severe neurological outcome or death at 6 months compared to survivors without neurological sequelae (odds ratio [95% confidence interval] 1.50 [1.04–2.19]), after adjustment for age, time between CA and return of spontaneous circulation, lactate and neuron-specific enolase levels. In Kaplan-Meier survival analysis, patients with elevated m¹A/A levels showed a lower probability of survival at 6 months (p = 0.003). CONCLUSION: This study provides the first evidence that m1A RNA methylation, reflected by the m1A/A ratio, is associated with neurological outcome and death at 6 months after CA. Although these findings require validation, they raise the possibility that m¹A RNA methylation could help to improve prognostication after CA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenosineHeart ArrestRNAHumansFemaleMaleBiomarkersMiddle AgedAgedRNA Methylation

Stichwörter der Autor:innen

BiomarkersCardiac arrest – prognosticationRNA methylation

Substanzen

AdenosineBiomarkersRNAN-methyladenosine

Autor:innen und Institutionen

  • Cardiovascular Research Unit, Department of Precision Health, Institute of Health, 1A-B rue Edison, Strassen, L-1445, Luxembourg.
  • Department of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia.
  • Metabolomics Platform, Department of Cancer Research, Institute of Health, 1A-B rue Edison, Strassen, L-1445, Luxembourg.
  • Bioinformatics and AI Unit, Department of Medical Informatics, Luxembourg institute of Health, Strassen, Luxembourg.
  • Department of Anesthesia and Intensive Care Medicine, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg.
  • Department of Life Sciences and Medicine, Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.

Förderung

  • Fondation Coeur Daniel Wagner
  • Ministère de l'Enseignement Supérieur et de la Recherche

Zitieren

APA

Stopa, V., Sopic, M., Bernardin, F., Legrave, N. M., Zhang, L., Stammet, P., & Devaux, Y. (2026). Blood N1-methyladenosine (m1A) RNA modification and outcome after cardiac arrest. Critical Care. https://doi.org/10.1186/s13054-026-05906-0

Vancouver

Stopa V, Sopic M, Bernardin F, Legrave NM, Zhang L, Stammet P, et al. Blood N1-methyladenosine (m1A) RNA modification and outcome after cardiac arrest. Critical Care. 2026. doi:10.1186/s13054-026-05906-0

BibTeX
@article{Stopa2026,
  author = {Stopa, Victoria and Sopic, Miron and Bernardin, François and Legrave, Nathalie M and Zhang, Lu and Stammet, Pascal and Devaux, Yvan},
  title = {Blood N1-methyladenosine (m1A) RNA modification and outcome after cardiac arrest},
  journal = {Critical Care},
  year = {2026},
  doi = {10.1186/s13054-026-05906-0}
}
Kostenlos starten →